← 返回

基于纳米颗粒的免疫工程策略用于增强癌症免疫治疗

英文原题:Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy.

查看英文原题

Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy.

PubMed 2023/12/14(内容时间) J Control Release Q1 · IF 12.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

癌症免疫疗法是一种突破性的策略,与其他治疗策略(如手术、化疗或放疗)相比,已经彻底改变了肿瘤学领域。然而,癌症复杂性、肿瘤异质性和免疫逃逸已成为免疫疗法临床应用的主要障碍。此外,由于患者的高反应性、治疗持续时间长和费用昂贵,传统免疫疗法会引起许多有害的副作用。纳米技术被认为是一种变革性方法,通过利用纳米载体优越的物理化学性质,创建高度靶向的组织递送系统,从而增强免疫疗法的效力。这些有利特征包括巨大的比表面积,这增强了与免疫系统的相互作用。此外,精细修饰表面化学的能力使得实现可控和持续释放特性成为可能。这些进展显著提高了免疫疗法的潜力,使其比以往任何时候都更强大。在这篇综述中,我们介绍了基于靶向不同主要免疫细胞(包括T细胞、树突状细胞、NK 细胞和肿瘤相关巨噬细胞)策略的最新纳米载体在癌症免疫疗法中的应用。我们还概述了纳米技术在癌症免疫疗法中的作用和意义。

展开英文摘要原文

Cancer immunotherapy is a groundbreaking strategy that has revolutionized the field of oncology compared to other therapeutic strategies, such as surgery, chemotherapy, or radiotherapy.

However, cancer complexity, tumor heterogeneity, and immune escape have become the main hurdles to the clinical application of immunotherapy.

Moreover, conventional immunotherapies cause many harmful side effects owing to hyperreactivity in patients, long treatment durations and expensive cost. Nanotechnology is considered a transformative approach that enhances the potency of immunotherapy by capitalizing on the superior physicochemical properties of nanocarriers, creating highly targeted tissue delivery systems. These advantageous features include a substantial specific surface area, which enhances the interaction with the immune system.

In addition, the capability to finely modify surface chemistry enables the achievement of controlled and sustained release properties. These advances have significantly increased the potential of immunotherapy, making it more powerful than ever before. In this review, we introduce recent nanocarriers for application in cancer immunotherapy based on strategies that target different main immune cells, including T cells, dendritic cells, natural killer cells, and tumor-associated macrophages.

We also provide an overview of the role and significance of nanotechnology in cancer immunotherapy.

论文信息

作者
Dang BN、Kwon TK、Lee S、Jeong JH、Yook S
第一作者单位
College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.South Korea
通讯作者单位
Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea. Electronic address: ysimmyung@skku.edu.South Korea
文献类型
综述 · 非美国政府资助研究
期刊
Journal of controlled release : official journal of the Controlled Release Society2024 Jan
原文标识
PubMed 38081328 · DOI 10.1016/j.jconrel.2023.12.007